GlobalData on MSN

Marea reports positive Phase I results for MAR002 trial in acromegaly

Single-ascending doses of MAR002 showed a favourable tolerability and safety profile with no drug-related safety signals ...
Medical Dialogues

NTA notifies subject-wise NEET 2026 syllabus, check complete details here

The National Testing Agency (NTA) has issued the subject wise NEET 2026 syllabus on this website soon after the NMC released ...
Yahoo Finance

T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma

BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug ...
Brattleboro Reformer

T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma

Don't miss the big stories. Like us on Facebook. BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has ...
Hosted on MSN

T Maximum CAR T therapy clears FDA for phase II trial

BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug ...
MarketWatch

T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma

The MarketWatch News Department was not involved in the creation of this content. BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, ...